Questions: Psychopharmacology: Principles and Mechanisms

Question 1

Both morphine and naloxone act on opioid receptors. A student predicts they should produce similar behavioral effects since they target the same receptor system. Why is this prediction wrong?

• A. Morphine and naloxone act on different subtypes of opioid receptor, so their molecular targets are unrelated
• B. The student is correct — drugs acting on the same receptor always produce qualitatively similar effects
• C. Morphine is an opioid agonist (activates receptors, producing analgesia and euphoria) while naloxone is an antagonist (occupies those same receptors without activating them, blocking morphine and reversing overdose) — same receptor, opposite mechanism, opposite outcomes
• D. Morphine acts on peripheral opioid receptors while naloxone acts centrally, which is why their effects differ

Answer: (C)

This is the foundational lesson of mechanism-of-action: knowing which receptor a drug targets is not sufficient. You must also know whether the drug activates or blocks it. Morphine is an agonist — it activates opioid receptors just as endogenous endorphins do, producing pain relief and euphoria. Naloxone is a competitive antagonist — it binds opioid receptors with high affinity but produces no activation, simply displacing morphine and blocking further agonist access. Two drugs, same target, opposite mechanisms, opposite behavioral effects. Receptor identity and mechanistic direction are both required to predict what a drug will do.

Question 2

SSRIs increase serotonergic signaling by blocking the serotonin reuptake transporter rather than by directly activating serotonin receptors. What follows clinically from this mechanistic distinction?

• A. SSRIs are less effective than direct serotonin agonists because indirect mechanisms are always less potent
• B. Since SSRIs don't activate receptors directly, they cannot cause serotonin syndrome regardless of dosage or combination
• C. SSRIs depend on endogenous serotonin release to work and enhance its effect by prolonging its presence at the synapse; this transporter selectivity shapes their receptor specificity, temporal dynamics, and side effect profile differently from direct receptor agonists
• D. SSRIs produce effects identical to direct serotonin agonists, merely with a delay due to the indirect mechanism

Answer: (C)

The reuptake-inhibitor mechanism is fundamentally different from direct receptor activation. SSRIs require the neuron to release serotonin in the first place — they then extend how long that serotonin stays active by blocking its clearance. This means the drug's effect is tied to natural release patterns, producing a more physiological temporal profile than direct agonism. Because the SSRI never touches the receptor, it doesn't directly activate all serotonin receptor subtypes; the enhancement is through increased occupancy by endogenous serotonin at naturally-targeted receptors. This specificity compared to a broad serotonin agonist explains the differing side effect profiles. And option B is wrong: excess serotonergic stimulation from any mechanism — including reuptake inhibition combined with other serotonergic drugs — can cause serotonin syndrome.

Question 3

Tolerance to a drug develops primarily because the body metabolizes it more rapidly over time, so larger doses are needed to achieve the same blood concentration.

• T. True
• F. False

Answer: False

False — while metabolic tolerance (induction of liver enzymes) can contribute in some cases, the mechanism emphasized in psychopharmacology is pharmacodynamic tolerance: receptor downregulation. When a receptor is persistently activated by an agonist, the cell reduces its responsiveness by decreasing the number of functional surface receptors or reducing their coupling efficiency. This is a cellular-level adaptation: the same drug concentration activates fewer receptors, so more drug is needed for the same effect. This downregulation is also the mechanism behind physical dependence: when the agonist is removed, the under-expressed receptor population is now insufficient to respond normally to endogenous transmitters, producing withdrawal symptoms.

Question 4

Withdrawal symptoms from a chronically administered agonist drug are often the mirror image of the drug's original effects, because the brain has downregulated receptors to compensate for persistent activation and is now under-responsive to its own neurotransmitters.

• T. True
• F. False

Answer: True

True. This logical relationship between tolerance and withdrawal is one of the most important clinical principles in psychopharmacology. If a drug produces analgesia, euphoria, and sedation by activating opioid receptors, then downregulation of those receptors during chronic use means the natural endorphin system can no longer produce adequate analgesia or mood regulation after drug removal — producing pain hypersensitivity, dysphoria, and agitation. The same principle applies across drug classes: stimulant withdrawal produces fatigue and depression (opposite of stimulation); benzodiazepine withdrawal produces anxiety and seizures (opposite of anxiolysis and sedation). Mechanism predicts the withdrawal syndrome.

Question 5

Explain why knowing which receptor a drug binds to is insufficient to predict its behavioral effects. What additional information is required?

Model answer: At minimum, you need to know: (1) whether the drug is an agonist, antagonist, or partial agonist at that receptor — same target, opposite mechanisms produce opposite effects (morphine vs. naloxone); (2) at which step in synaptic transmission it acts — does it block reuptake, increase transmitter release, inhibit synthesis, or bind the receptor directly? These distinctions produce different temporal dynamics, receptor specificity, and side effect profiles even for drugs that ultimately increase signaling in the same neurotransmitter system; (3) which other receptors, transporters, or enzymes it affects as secondary targets — most drugs are not perfectly selective, and off-target binding explains side effects. The drug's full mechanistic profile — not just its primary receptor — determines its behavioral effects, tolerability, dependence potential, and interaction risks.

The principle is mechanism selectivity: the more completely you understand a drug's profile of targets and what it does at each, the more you can predict rather than merely observe its effects. This is what separates rational pharmacotherapy from empirical trial-and-error.